Contact
searchSearch
HMP Global
Login

News

Laurence Albiges, MD, PhD, Gustave Roussy
Videos
Addition of Cabozantinib to Nivolumab-Ipilimumab for Advanced Renal Cell Carcinoma in the First-Line Setting
03/13/2025
Laurence Albiges, MD, PhD, discusses the final results from the COSMIC-313 trial which evaluated cabozantinib plus nivolumab and ipilimumab for patients with previously untreated advanced renal cell carcinoma.
Laurence Albiges, MD, PhD, discusses the final results from the COSMIC-313 trial which evaluated cabozantinib plus nivolumab and ipilimumab for patients with previously untreated advanced renal cell carcinoma.
Laurence Albiges, MD, PhD,...
03/13/2025
Oncology
Matthew Zibelman, MD
Conference Coverage
Nivolumab Plus Axitinib for Previously-Treated Patients With Advanced Renal Cell Carcinoma
02/27/2025
Matthew Zibelman, MD
Matthew Zibelman, MD, discusses results from a phase 1/2 study which evaluated nivolumab plus axitinib as a treatment option for previously-treated patients with advanced renal cell carcinoma.
Matthew Zibelman, MD, discusses results from a phase 1/2 study which evaluated nivolumab plus axitinib as a treatment option for previously-treated patients with advanced renal cell carcinoma.
Matthew Zibelman, MD, discusses...
02/27/2025
Oncology
Sahil Doshi, MD
Conference Coverage
Impact of Ipilimumab-Nivolumab Dosage for Patients With Metastatic Renal Cell Carcinoma
02/27/2025
Sahil Doshi, MD
Sahil Doshi, MD, discusses retrospective study results which demonstrated that patients with metastatic renal cell carcinoma who had less than the recommended 4 doses of ipilimumab plus nivolumab had similar overall survival outcomes as those...
Sahil Doshi, MD, discusses retrospective study results which demonstrated that patients with metastatic renal cell carcinoma who had less than the recommended 4 doses of ipilimumab plus nivolumab had similar overall survival outcomes as those...
Sahil Doshi, MD, discusses...
02/27/2025
Oncology
Francesca Jackson-Spence, MBChB
Conference Coverage
Durvalumab Plus Savolitinib for Patients With MET-Driven Advanced Papillary Renal Cancer
02/26/2025
Francesca Jackson-Spence, MBChB
Francesca Jackson-Spence, MBChB, discusses final efficacy and ctDNA data from the CALYPSO trial which demonstrated that durvalumab plus savolitinib prolonged efficacy among patients with MET-driven advanced papillary renal cancer.
Francesca Jackson-Spence, MBChB, discusses final efficacy and ctDNA data from the CALYPSO trial which demonstrated that durvalumab plus savolitinib prolonged efficacy among patients with MET-driven advanced papillary renal cancer.
Francesca Jackson-Spence, MBChB,...
02/26/2025
Oncology
Katy Beckermann, MD
Conference Coverage
Lenvatinib Plus Belzutifan Shows Promise for Advanced Clear Cell Renal Cell Carcinoma
02/25/2025
Katy Beckermann, MD
Katy Beckermann, MD, discusses results from the KEYMAKER-U03 Substudy 03B, evaluating pembrolizumab in combination with targeted therapy agents for patients with advanced clear cell renal cell carcinoma.
Katy Beckermann, MD, discusses results from the KEYMAKER-U03 Substudy 03B, evaluating pembrolizumab in combination with targeted therapy agents for patients with advanced clear cell renal cell carcinoma.
Katy Beckermann, MD, discusses...
02/25/2025
Oncology
Conference Coverage
Long-Term Benefit of Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma
02/13/2025
Allison Casey
According to the long-term data from the phase 3 CheckMate 9ER trial, nivolumab plus cabozantinib continued to show an efficacy benefit, compared with sunitinib among untreated patients with advanced renal cell carcinoma.
According to the long-term data from the phase 3 CheckMate 9ER trial, nivolumab plus cabozantinib continued to show an efficacy benefit, compared with sunitinib among untreated patients with advanced renal cell carcinoma.
According to the long-term data...
02/13/2025
Oncology
Conference Coverage
First-Line Cabozantinib Plus Nivolumab and Ipilimumab for Advanced Renal Cell Carcinoma
02/13/2025
Allison Casey
In the phase 3 COSMIC-313 trial, final results indicated that cabozantinib plus nivolumab and ipilimumab maintained its PFS benefit with comparable OS when compared with placebo plus nivolumab and ipilimumab among patients with intermediate...
In the phase 3 COSMIC-313 trial, final results indicated that cabozantinib plus nivolumab and ipilimumab maintained its PFS benefit with comparable OS when compared with placebo plus nivolumab and ipilimumab among patients with intermediate...
In the phase 3 COSMIC-313 trial,...
02/13/2025
Oncology
Conference Coverage
First-Line Lenvatinib Plus Tislelizumab Demonstrates Promise for Patients With Fumarate Hydratase-Deficient Renal Cell Carcinoma
02/13/2025
Stephanie Holland
According to preliminary results from a phase 2 study, first-line lenvatinib plus tislelizumab demonstrated promising efficacy and safety among patients with advanced fumarate hydratase-deficient renal cell carcinoma.
According to preliminary results from a phase 2 study, first-line lenvatinib plus tislelizumab demonstrated promising efficacy and safety among patients with advanced fumarate hydratase-deficient renal cell carcinoma.
According to preliminary results...
02/13/2025
Oncology
Conference Coverage
First-Line Lenvatinib Plus Tislelizumab Demonstrates Promise for Patients With Fumarate Hydratase-Deficient Renal Cell Carcinoma
02/13/2025
Stephanie Holland
According to preliminary results from a phase 2 study, first-line lenvatinib plus tislelizumab demonstrated promising efficacy and safety among patients with advanced fumarate hydratase-deficient renal cell carcinoma.
According to preliminary results from a phase 2 study, first-line lenvatinib plus tislelizumab demonstrated promising efficacy and safety among patients with advanced fumarate hydratase-deficient renal cell carcinoma.
According to preliminary results...
02/13/2025
Oncology
News
Avelumab Plus Axitinib Demonstrates Long-Term Efficacy, Safety for Patients With Advanced Renal Cell Carcinoma
01/08/2025
Stephanie Holland
Final results from the phase 3 JAVELIN Renal 101 trial demonstrated that avelumab plus axitinib showed long-term efficacy and safety among patients with previously untreated advanced renal cell carcinoma.
Final results from the phase 3 JAVELIN Renal 101 trial demonstrated that avelumab plus axitinib showed long-term efficacy and safety among patients with previously untreated advanced renal cell carcinoma.
Final results from the phase 3...
01/08/2025
Oncology

Recent News

News
Modakafusp Alfa Demonstrates Antitumor Activity Among Patients With Relapsed/Refractory Multiple Myeloma
04/02/2025
Emily Estrada
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose,...
04/02/2025
Oncology
News
Quadruplet Therapy Demonstrates Efficacy for Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma
04/02/2025
Emily Estrada
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with...
04/02/2025
Oncology
News
Co-Occurrence of High-Risk Cytogenetic Abnormalities as a Predictive Marker for Multiple Myeloma
04/02/2025
Emily Estrada
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more...
04/02/2025
Oncology
News
Pembrolizumab Plus Bevacizumab Shows Promise Among Previously Untreated Patients With Melanoma Brain Metastases
04/01/2025
Stephanie Holland
According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.
According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.
According to results from a...
04/01/2025
Oncology
News
Outcomes Without Adjuvant Radioactive Iodine Among Pediatric Patients With Papillary Thyroid Cancer
04/01/2025
Allison Casey
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective...
04/01/2025
Oncology
News
Lenvatinib Plus High-Dose Radioiodine Therapy Shows Promise for Patients With Metastatic Well-Differentiated Thyroid Cancer
04/01/2025
Allison Casey
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of...
04/01/2025
Oncology
News
Zenocutuzumab Demonstrates Durable Activity in NRG1 Fusion–Positive Solid Tumors
03/31/2025
Janelle Bradley
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study...
03/31/2025
Oncology
FDA Approval
Durvalumab Approved for Muscle Invasive Bladder Cancer
03/31/2025
Allison Casey
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant...
03/31/2025
Oncology
FDA Approval
FDA Expands Approval of Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer
03/28/2025
Stephanie Holland
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the...
03/28/2025
Oncology
FDA Approval
FDA Approves Cabozantinib for Patients With Locally Advanced or Metastatic Well-Differentiated pNETs and epNETs
03/26/2025
Stephanie Holland
Based on results from the CABINET trial, the FDA has approved cabozantinib for patients 12 years of age and older with unresectable locally advanced or metastatic well-differentiated pNETs and epNETs who experienced disease progression after...
Based on results from the CABINET trial, the FDA has approved cabozantinib for patients 12 years of age and older with unresectable locally advanced or metastatic well-differentiated pNETs and epNETs who experienced disease progression after...
Based on results from the...
03/26/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use